| Tumor evolution and drug response in patient-derived organoid models of bladder cancer SH Lee, W Hu, JT Matulay, MV Silva, TB Owczarek, K Kim, CW Chua, ... Cell 173 (2), 515-528. e17, 2018 | 780 | 2018 |
| Next-generation sequencing of nonmuscle invasive bladder cancer reveals potential biomarkers and rational therapeutic targets EJ Pietzak, A Bagrodia, EK Cha, EN Drill, G Iyer, S Isharwal, I Ostrovnaya, ... European urology 72 (6), 952-959, 2017 | 368 | 2017 |
| Clonal relatedness and mutational differences between upper tract and bladder urothelial carcinoma F Audenet, S Isharwal, EK Cha, MTA Donoghue, EN Drill, I Ostrovnaya, ... Clinical Cancer Research 25 (3), 967-976, 2019 | 228 | 2019 |
| Genetic determinants of cisplatin resistance in patients with advanced germ cell tumors A Bagrodia, BH Lee, W Lee, EK Cha, JP Sfakianos, G Iyer, EJ Pietzak, ... Journal of Clinical Oncology 34 (33), 4000-4007, 2016 | 178 | 2016 |
| Genomic differences between “primary” and “secondary” muscle-invasive bladder cancer as a basis for disparate outcomes to cisplatin-based neoadjuvant chemotherapy EJ Pietzak, EC Zabor, A Bagrodia, J Armenia, W Hu, A Zehir, S Funt, ... European urology 75 (2), 231-239, 2019 | 146 | 2019 |
| An approach for normalization and quality control for NanoString RNA expression data A Bhattacharya, AM Hamilton, H Furberg, E Pietzak, MP Purdue, ... Briefings in bioinformatics 22 (3), bbaa163, 2021 | 107 | 2021 |
| The impact of plasmacytoid variant histology on the survival of patients with urothelial carcinoma of bladder after radical cystectomy Q Li, M Assel, NE Benfante, EJ Pietzak, HW Herr, M Donat, EK Cha, ... European urology focus 5 (1), 104-108, 2019 | 81 | 2019 |
| Neoadjuvant atezolizumab with gemcitabine and cisplatin in patients with muscle-invasive bladder cancer: a multicenter, single-arm, phase II trial SA Funt, M Lattanzi, K Whiting, H Al-Ahmadie, C Quinlan, MY Teo, ... Journal of Clinical Oncology 40 (12), 1312-1322, 2022 | 77 | 2022 |
| Multicenter phase II clinical trial of gemcitabine and cisplatin as neoadjuvant chemotherapy for patients with high-grade upper tract urothelial carcinoma JA Coleman, W Yip, NC Wong, DD Sjoberg, BH Bochner, G Dalbagni, ... Journal of Clinical Oncology 41 (8), 1618-1625, 2023 | 63 | 2023 |
| Histology of testicular biopsies obtained for experimental fertility preservation protocol in boys with cancer EJ Pietzak, GE Tasian, SK Tasian, RL Brinster, C Carlson, JP Ginsberg, ... The Journal of urology 194 (5), 1420-1424, 2015 | 61 | 2015 |
| Heavy cigarette smoking and aggressive bladder cancer at initial presentation EJ Pietzak, P Mucksavage, TJ Guzzo, SB Malkowicz Urology 86 (5), 968-973, 2015 | 51 | 2015 |
| Genomic landscape of inverted urothelial papilloma and urothelial papilloma of the bladder S Isharwal, W Hu, J Sarungbam, Y Chen, A Gopalan, SW Fine, SK Tickoo, ... The Journal of pathology 248 (3), 260-265, 2019 | 49 | 2019 |
| Modeling biological and genetic diversity in upper tract urothelial carcinoma with patient derived xenografts K Kim, W Hu, F Audenet, N Almassi, AJ Hanrahan, K Murray, A Bagrodia, ... Nature communications 11 (1), 1975, 2020 | 46 | 2020 |
| Contemporary staging for muscle-invasive bladder cancer: accuracy and limitations PJ Hensley, V Panebianco, E Pietzak, A Kutikov, R Vikram, MD Galsky, ... European Urology Oncology 5 (4), 403-411, 2022 | 43 | 2022 |
| Prognostic value of TERT alterations, mutational and copy number alterations burden in urothelial carcinoma S Isharwal, F Audenet, E Drill, EJ Pietzak, G Iyer, I Ostrovnaya, E Cha, ... European urology focus 5 (2), 201-204, 2019 | 42 | 2019 |
| Identification of a novel inflamed tumor microenvironment signature as a predictive biomarker of bacillus Calmette-Guérin immunotherapy in non–muscle-invasive bladder cancer JS Damrauer, KR Roell, MA Smith, X Sun, EL Kirk, KA Hoadley, ... Clinical Cancer Research 27 (16), 4599-4609, 2021 | 39 | 2021 |
| Genomic heterogeneity as a barrier to precision oncology in urothelial cancer TN Clinton, Z Chen, H Wise, AT Lenis, S Chavan, MTA Donoghue, ... Cell reports 41 (12), 2022 | 36 | 2022 |
| Fibroblast growth factor receptor 3 alteration status is associated with differential sensitivity to platinum-based chemotherapy in locally advanced and metastatic urothelial … MY Teo, JM Mota, KA Whiting, HA Li, SA Funt, CH Lee, DB Solit, ... European urology 78 (6), 907-915, 2020 | 36 | 2020 |
| FOXA1 repression drives lineage plasticity and immune heterogeneity in bladder cancers with squamous differentiation JI Warrick, W Hu, H Yamashita, V Walter, L Shuman, JM Craig, LL Gellert, ... nature communications 13 (1), 6575, 2022 | 33 | 2022 |
| Genomic profile of urothelial carcinoma of the upper tract from ureteroscopic biopsy: feasibility and validation using matched radical nephroureterectomy specimens A Bagrodia, F Audenet, EJ Pietzak, K Kim, KS Murray, EK Cha, ... European urology focus 5 (3), 365-368, 2019 | 33 | 2019 |
